XXXX . Efficacy and safety of intrapericardial treatment with @entity900 .

@entity1 @entity0 @entity2294 @entity5 @entity900 @entity2 @entity2615 @entity741 @entity978 @entity694
AIMS: To evaluate the clinical efficacy, safety, and long-term effect of intrapericardial treatment with @entity900 in large @entity2294 . METHODS AND RESULTS: Out of the registry of 260 @entity1 undergoing pericardiocentesis, 42 @entity1 with @entity2294 (69% males, mean age 58.8+/-13.2 years) were selected for treatment with @entity900 (single instillation of 30 mg.m(-2) x 24h(-1)) in addition to the @entity5 -specific systemic chemotherapy. All @entity1 underwent clinical examination, echocardiography, pericardiocentesis, pericardioscopy, and epicardial biopsy. Pericardial effusion and biopsy analyses included biochemistry, cytology, serology, microbiology, histology, immunohistology, and PCR. The following @entity5 were established: @entity2 , 52.4%; @entity0 , 19.0%; @entity978 , 4.8%; @entity5 , 2.4%; @entity2615 , 2.4%; @entity694 , 4.8%; and undifferentiated @entity5 of unknown origin, 14.2%. @entity900 appeared to prevent recurrence of @entity2294 during the first 3 months of the follow-up in 92.8%, and after 6 months in 83.3% of the @entity1 . @entity2 @entity1 had fewer effusion relapses at the 6 months follow-up (4.5%) than @entity0 @entity1 (37.5%)(P<0.05). @entity741 occurred after 1/42 @entity900 instillations, but there were no other complications. CONCLUSION: Intrapericardial treatment with @entity900 appeared to successfully prevent recurrences of @entity2294 . The treatment was more successful in lung than in @entity0 @entity1 .
